3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
PR Newswire·- 3SBio reported its 2026 interim results, posting a revenue of RMB 4.53 billion and an adjusted operating net profit of RMB 1.44 billion, representing a 26.5% year-over-year increase. - The company advanced its innovation pipeline by securing marketing approvals for three Class 1 innovative drugs, advancing five products to the New Drug Application stage, and driving global clinical trials for PF-08634404. - 3SBio also expanded its multi-therapeutic portfolio across oncology, autoimmune diseases, and nephrology, while its Wind ESG rating was upgraded to "AA" for its sustainable development practices.Sino Biopharmaceutical surges 8% on 27% jump in adjusted H1 profit
HK Stock Market Update·HK Stocks Midday: Hang Seng Jumps Over 230 Pts; Gold Miners Surge, Insurers Rally
Market Pulse·- On August 21, Hong Kong stocks maintained an upward trend in the afternoon, with the Hang Seng Index rising 0.91% to 25,932.30 points. - Gold and resource stocks surged collectively driven by rising gold prices, while domestic insurance and financial stocks also strengthened. - The total market turnover reached approximately 1794 billion HKD, with technology and property stocks showing mixed performances.Sunshine Pharmaceutical climbs 4% after reporting 1H results
HK Stock Market Update·3SBio climbs 2% after mixed first-half earnings
HK Stock Market Update·3SBio climbs 4% in Hong Kong trading after BofA initiates Buy rating
HK Stock Market Update·3SBio gains 3% in Hong Kong as innovation drug stocks rally
HK Stock Market Update·3SBio climbs more than 3% in Hong Kong after BofA buy initiation
HK Stock Market Update·